Home » Stocks » CPRX

Catalyst Pharmaceuticals, Inc. (CPRX)

Stock Price: $3.70 USD 0.21 (6.02%)
Updated November 27, 1:00 PM EST - Market closed

Stock Price Chart

Key Info

Market Cap 383.50M
Revenue (ttm) 118.18M
Net Income (ttm) 71.48M
Shares Out 103.65M
EPS (ttm) 0.67
PE Ratio 5.52
Forward PE 8.73
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 27
Last Price $3.70
Previous Close $3.49
Change ($) 0.21
Change (%) 6.02%
Day's Open 3.53
Day's Range 3.51 - 3.72
Day's Volume 1,174,728
52-Week Range 2.55 - 5.28

More Stats

Market Cap 383.50M
Enterprise Value 256.38M
Earnings Date (est) Mar 17, 2021
Ex-Dividend Date n/a
Shares Outstanding 103.65M
Float 96.48M
EPS (basic) 0.69
EPS (diluted) 0.67
FCF / Share 0.43
Dividend n/a
Dividend Yield n/a
Earnings Yield 18.11%
FCF Yield 11.53%
Payout Ratio n/a
Shares Short 13.44M
Short Ratio 10.87
Short % of Float 13.93%
Beta 1.54
PE Ratio 5.52
Forward PE 8.73
P/FCF Ratio 8.67
PS Ratio 3.25
PB Ratio 2.31
Revenue 118.18M
Operating Income 40.69M
Net Income 71.48M
Free Cash Flow 44.21M
Net Cash 127.12M
Net Cash / Share 1.23
Gross Margin 74.08%
Operating Margin 34.43%
Profit Margin 60.50%
FCF Margin 37.41%
ROA 18.73%
ROE 60.93%
ROIC 487.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (5)

Buy 5
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$7.40*
(100.00% upside)
Low
5.50
Current: $3.70
High
9.00
Target: 7.40
*Average 12-month price target from 5 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue1020.50--------
Revenue Growth20361.27%---------
Gross Profit87.550.50--------
Operating Income31.82-35.30-18.68-19.28-20.40-14.59-10.31-5.22-6.08-4.51
Net Income31.88-34.00-18.41-18.07-20.23-15.51-12.15-4.08-6.39-4.01
Shares Outstanding10310385.8082.8880.8664.1445.4530.0321.7318.58
Earnings Per Share0.30-0.33-0.21-0.22-0.25-0.24-0.27-0.14-0.29-0.22
Operating Cash Flow34.61-26.15-13.74-17.96-18.02-12.94-9.88-5.14-4.99-3.76
Capital Expenditures-0.02-0.09--0.10-0.02-0.06-0.01-0.05--
Free Cash Flow34.59-26.24-13.74-18.06-18.04-13.00-9.89-5.19-4.99-3.76
Cash & Equivalents94.5353.4984.0240.4158.4139.2823.7215.436.045.49
Total Debt0.65---------
Net Cash / Debt93.8853.4984.0240.4158.4139.2823.7215.436.045.49
Assets11260.4585.3941.7160.1043.9125.3716.796.255.83
Liabilities24.759.674.422.404.638.673.982.172.490.31
Book Value87.6350.7880.9639.3155.4835.2421.3914.623.765.52
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Catalyst Pharmaceuticals, Inc.
Country United States
Employees 76
CEO Patrick J. McEnany

Stock Information

Ticker Symbol CPRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: CPRX
IPO Date November 8, 2006

Description

Catalyst Pharmaceuticals, a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.